Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.9 USD | -1.36% |
|
+4.69% | -57.82% |
06-20 | SAB Biotherapeutics, Inc. has Changed its Name to SAB BIO | CI |
06-07 | Brookline Capital Initiates SAB Biotherapeutics With Buy Rating, $8 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-57.82% | 27.13M | |
+16.46% | 122B | |
+21.70% | 116B | |
+22.18% | 27.03B | |
-21.83% | 20.36B | |
-16.89% | 16.43B | |
-18.67% | 15.91B | |
-44.74% | 15.6B | |
+62.81% | 14.94B | |
+3.15% | 13.59B |
- Stock Market
- Equities
- SABS Stock
- News SAB Biotherapeutics, Inc.
- Chardan Adjusts SAB Biotherapeutics Price Target to $10 From $17, Maintains Buy Rating